

TT 4/17  
2/26/01  
M.L.

PW Matter No. 0276603

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Patent Application of: )  
Darrell R. Anderson et al. )  
Application No. (Unassigned) ) Group Art Unit: Unassigned  
Filed: January 12, 2001 ) Examiner: Unassigned  
For: HUMAN B7.1-SPECIFIC PRIMATIZED )  
ANTIBODIES AND TRANSFECTOMAS )  
EXPRESSING SAID ANTIBODIES )

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:




Prior to examination, kindly cancel Claims 1-20 (all of the original claims) and insert  
the following new claims:

*Sub D1*  
--21. A method of treating B cell lymphoma comprising administering a  
therapeutically effective amount of an anti-B7 antibody.

*A2*  
*cm't*  
22. The method of claim 21 wherein said B7 is B7.1 and/or B7.2.

*Sub D2*  
23. The method of claim 21 wherein said B7 is B7.1.

24. The method of claim 21 wherein said anti-B7 antibody binds the same epitope  
as an anti-B7.1 antibody selected from the group consisting of 16C10, 7C10, 20C9 and 7B6.

25. The method of claim 21 wherein said antibody is a depleting antibody.
26. The method of claim 21 wherein said antibody is a non-depleting antibody.
- A2  
concl  
  
Sub B1  

27. The method of claim 21 wherein said antibody is a primate antibody.
28. The method of claim 21 wherein said antibody is administered repetitively.
29. The method of claim 21 wherein said antibody is administered parenterally.
30. The method of claim 29 wherein parenterally includes intravenous,  
intraperitoneal, intramuscular, subcutaneous and rectal administration.  

31. The method of claim 21 wherein the antibody comprises human gamma-1 or  
gamma-4 constant regions.--
- 
- ADD  
B2  


Remarks

Entry of the foregoing amendments and favorable consideration on the merits is  
respectfully requested.

Specific support for these claims may be found at page 32 (line 16), page 30 (lines 11-  
23) and pages 34-35 of the subject application.